Education
About Us
Working with TipRanks
Follow Us
Aethlon Medical Inc (AEMD)
NASDAQ:AEMD
AEMD Stock Chart & Stats
$2.01
-$0.16(-18.80%)
At close: 4:00 PM EST
$2.01
-$0.16(-18.80%)
Day’s Range― - ―
52-Week Range$1.85 - $42.40
Previous CloseN/A
Volume1.62M
Average Volume (3M)688.41K
Market Cap
$2.46M
Enterprise Value-$5.12M
Total Cash (Recent Filing)$6.96M
Total Debt (Recent Filing)$417.52K
Price to Earnings (P/E)―
Beta1.20
Next Earnings
Jun 25, 2026EPS Estimate
-2.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.45
Shares Outstanding1,315,110
10 Day Avg. Volume703,784
30 Day Avg. Volume688,413
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.87
Price to Sales (P/S)0.00
P/FCF Ratio-0.58
Enterprise Value/Market Cap-2.08
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit9.35
Enterprise Value/Ebitda0.46
Forecast
1Y Price Target
$2.05Price Target Upside1.99% Upside
Rating ConsensusHold
Number of Analyst Covering2
EPS Forecast (FY)-9.55
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Combination Therapy PotentialAn amended protocol allowing combination treatment with pembrolizumab enables assessment of synergistic effects that may improve response rates compared with monotherapy.
Enrollment AccelerationManagement believes enrollment into the next cohort could be accelerated by a pool of pre-screened participants, which would speed patient recruitment if regulatory approval is obtained.
Scientific Rationale From External EvidenceExternal clinical evidence suggesting that multiple Hemopurifier treatments may be needed supports the scientific rationale that repeated treatments could enhance tumor particle removal and improve immunotherapy response.
Bears Say
Financing RiskLimited cash resources combined with no revenues and an operating loss increase the likelihood that additional capital will be required to sustain clinical development.
Gating Clinical MilestoneProgression to the next cohort requires an independent Data Safety Monitoring Board review, creating a gating clinical milestone that could delay trial advancement.
High-risk Investor ProfileAnalyst highlights multiple risk categories including clinical, commercial, collaboration, dilution, legal, intellectual property and competition, reflecting a high-risk profile that raises uncertainty about commercialization prospects.
Aethlon Medical News
AEMD FAQ
What was Aethlon Medical Inc’s price range in the past 12 months?
Aethlon Medical Inc lowest stock price was $1.85 and its highest was $42.40 in the past 12 months.
What is Aethlon Medical Inc’s market cap?
Aethlon Medical Inc’s market cap is $2.46M.
When is Aethlon Medical Inc’s upcoming earnings report date?
Aethlon Medical Inc’s upcoming earnings report date is Jun 25, 2026 which is in 114 days.
How were Aethlon Medical Inc’s earnings last quarter?
Aethlon Medical Inc released its earnings results on Feb 12, 2026. The company reported -$2.45 earnings per share for the quarter, beating the consensus estimate of -$2.75 by $0.3.
Is Aethlon Medical Inc overvalued?
According to Wall Street analysts Aethlon Medical Inc’s price is currently Undervalued.
Does Aethlon Medical Inc pay dividends?
Aethlon Medical Inc does not currently pay dividends.
What is Aethlon Medical Inc’s EPS estimate?
Aethlon Medical Inc’s EPS estimate is -2.01.
How many shares outstanding does Aethlon Medical Inc have?
Aethlon Medical Inc has 1,315,110 shares outstanding.
What happened to Aethlon Medical Inc’s price movement after its last earnings report?
Aethlon Medical Inc reported an EPS of -$2.45 in its last earnings report, beating expectations of -$2.75. Following the earnings report the stock price went down -1.01%.
Which hedge fund is a major shareholder of Aethlon Medical Inc?
Currently, no hedge funds are holding shares in AEMD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Aethlon Medical Inc
Aethlon Medical, Inc., a medical technology company, focuses on developing products to diagnose and treat life and organ threatening diseases in the United States. The company develops Aethlon Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses from the human circulatory system, including removal of COVID-19 virus, associated variants, and related exosomes. Aethlon Medical, Inc. has a collaboration with the University of Pittsburgh Medical Center Hillman Cancer Center for studies related to head and neck cancer. The company was founded in 1999 and is based in San Diego, California.
AEMD Earnings Call
Q3 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call conveyed meaningful operational and scientific progress—most notably favorable safety signals in the Australian oncology trial, expansion of EV research with multiple preclinical publications, a potential pathway to simplify delivery (SLAMB), and a sizable 27% reduction in nine-month operating expenses. Offsetting these positives are near-term financial constraints and mixed quarterly financials: a $7.0 million cash balance that may limit runway, a quarterly operating expense increase of 13.6% and higher operating loss, reduced interest income, and program/timing uncertainties (DSMB decisions and SLAMB regulatory/technical work still preliminary). Overall, the update reflects constructive clinical and R&D momentum but with clear near-term financial and operational risks that leave the outlook balanced.View all AEMD earnings summariesAEMD Stock 12 Month Forecast
Average Price Target
$2.05
▲(1.99% Upside)
Technical Analysis
―
Catheter Precision
―
Bluejay Diagnostics
―
Tivic Health Systems
―
Autonomix Medical, Inc.
―
Ownership Overview
26.68% Insiders
0.10% Mutual Funds
― Other Institutional Investors
73.22% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---